Goldman Sachs Upgrades Mattel to Buy, Raises Price Target to $31
Goldman Sachs analyst Michael Ng upgrades Mattel (NASDAQ:MAT) from Neutral to Buy and raises the price target from $30 to $31.
Goldman Sachs Downgrades Upstart Hldgs to Sell, Lowers Price Target to $14
Goldman Sachs analyst Michael Ng downgrades Upstart Hldgs (NASDAQ:UPST) from Neutral to Sell and lowers the price target from $40 to $14.
Goldman Sachs Initiates Coverage On Affirm Holdings with Neutral Rating, Announces Price Target of $22
Goldman Sachs analyst Michael Ng initiates coverage on Affirm Holdings (NASDAQ:AFRM) with a Neutral rating and announces Price Target of $22.
Keybanc Maintains Overweight on T-Mobile US, Raises Price Target to $161
Keybanc analyst Brandon Nispel maintains T-Mobile US (NASDAQ:TMUS) with a Overweight and raises the price target from $155 to $161.
Keybanc Maintains Overweight on Match Group, Lowers Price Target to $90
Keybanc analyst Justin Patterson maintains Match Group (NASDAQ:MTCH) with a Overweight and lowers the price target from $125 to $90.
Diebold Nixdorf Shares Pop On Rating Upgrade: Key Takeaways
Wedbush analyst Matt Bryson upgraded Diebold Nixdorf Inc (NYSE: DBD) from Neutral to Outperform with a $5 price target. The projection reflected its strong…
Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path
Yesterday, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced data from the new interim analysis of the Phase 3 REGENERATE trial evaluating obeticholic acid in…
Telsey Advisory Says Costco Is ‘Executing Well’; Sees Notable Upside
Telsey Advisory Group analyst Joseph Feldman reiterated its Outperform rating on Costco Wholesale Corp (NASDAQ:COST) shares with a price target of $590 (17%…
Needham Reasons How TSMC’s N3E May Become Industry’s Most Favored FinFET Node
Needham analysts shared the key takeaways from Taiwan Semiconductor Manufacturing Company Ltd's (NYSE: TSM) 2022 Technology Symposium.
Why This Small-Cap Stock Is Gaining More Than 10% Today?
Chardan has initiated coverage of Immuneering Corp (NASDAQ:IMRX) with a Buy rating and a price target of $18. Immuneering’s lead candidate, IMM-1-104, an…